Cost-Related Medication Non-Adherence Declined After the Inflation Reduction Act

Why It Matters

Improved adherence can reduce cardiovascular events and health‑care spending, showing cost caps are an effective public‑health lever. The results also point to potential gains if similar measures extend to Medicaid and private insurers.

Key Takeaways

• IRA subsidies cut non‑adherence by 5.5 percentage points.
• 70,000 low‑income seniors avoided missed doses in 2024.
• Medicare adherence improved 2.1% versus privately insured peers.
• No change in overall financial strain despite better adherence.
• Clinicians must educate patients on new out‑of‑pocket caps.

Pulse Analysis

The 2024 rollout of the Inflation Reduction Act’s drug‑cost provisions marked a pivotal shift for Medicare, eliminating the 5 % catastrophic coinsurance and expanding subsidy eligibility. By capping out‑of‑pocket expenses, the law directly addressed a long‑standing barrier to medication access for seniors, especially those near the federal poverty line. This policy change aligns with broader federal efforts to temper inflation while preserving the fiscal health of the Medicare program.

A recent NIH‑funded study leveraged the National Health Interview Survey to quantify the policy’s impact on cardiovascular patients and other high‑risk groups. Researchers observed a 5.5‑percentage‑point reduction in cost‑related non‑adherence among newly eligible beneficiaries, equating to about 70,000 seniors who maintained their prescribed regimens in 2024. When benchmarked against a control cohort of privately insured adults aged 60‑64, Medicare participants experienced a 2.1 % greater adherence gain, even though overall financial strain metrics did not shift, suggesting the caps specifically targeted medication‑related costs.

The findings carry weight for payers, providers, and policymakers. Better adherence is linked to fewer hospitalizations and lower long‑term expenditures, indicating that cost‑containment mechanisms can yield both health and economic dividends. However, the study also uncovered a knowledge gap: many beneficiaries remain unaware of the new caps, limiting the policy’s full potential. Clinicians therefore have a critical role in educating patients, while legislators may consider extending similar caps to Medicaid and private plans to replicate Medicare’s early successes across the broader U.S. healthcare landscape.